CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

Company Overview

CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.

Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes. The company has assembled an intellectual property portfolio covering its lead compounds and key synthetic methods, positioning its programs for potential licensing or partnership opportunities that can support late-stage development and commercialization.

CNBX Pharmaceuticals’ management team brings together experts in pharmaceutical chemistry, clinical development and regulatory affairs to guide its programs through critical R&D milestones. As a clinical-stage enterprise, CNBX remains focused on advancing its lead assets toward first-in-human trials and forging strategic alliances to accelerate the delivery of next-generation cannabinoid-based therapies for patients with significant unmet medical needs.

Key Stats

• Today's Range: $0.0001 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0007
• Volume: 5.77 million shs
• Average Volume: 28.46 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CNBX
• CIK: 1343009
• Web: www.cannabics.com
• Phone: (877) 424-2429
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A